Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07357441 · ClinicalTrials.gov registry record
A Study to Evaluate the Demographics and Treatment Patterns of Myelofibrosis Patients Treated With Ruxolitinib in Turkey
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 355
- Enrollment target
NCT07357441: Completed study, sponsored by Novartis Pharmaceuticals.
NCT07357441 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 355 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07357441 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 355 participants
- Enrollment target
Study Summary
This was a non-interventional retrospective study. Data from patients who were diagnosed with myelofibrosis (MF) (primary MF, post-polycythemia vera MF \& post-essential thrombocythemia MF) and treated with ruxolitinib for at least 3 months collectively were collected. The baseline visit was the visit that the patient started ruxolitinib treatment. Data was collected between January 01, 2015 and December 31, 2022. The main baseline clinical and laboratory data of the cohort with at least 3 months of ruxolitinib treatment was documented in order to identify real life patient data in Turkey. All the data was transferred to a clinical report form (CRF), then to the Statistical Package for the Social Sciences (SPSS) software in an anonymous fashion. The source documents were secured for quality control of the data. The quality control of the data was controlled by an unbiased data entry coordinator.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 355 participants |
| Start Date | 2022-04-07 |
| Est. Completion | 2023-06-28 |
What the finished NCT07357441 record still lists
NCT07357441 is an observational study that tracks outcomes without assigning an intervention. The registered 355 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT07357441 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07357441 about?
NCT07357441 is a clinical study titled "A Study to Evaluate the Demographics and Treatment Patterns of Myelofibrosis Patients Treated With Ruxolitinib in Turkey". This was a non-interventional retrospective study. Data from patients who were diagnosed with myelofibrosis (MF) (primary MF, post-polycythemia vera MF \& post-essential thrombocythemia MF) and treated with ruxolitinib for at least 3 months collectively were collected. The baseline visit was the vis...
What is the current status of trial NCT07357441?
This trial is currently completed. The enrollment target is 355 participants. The study started on 2022-04-07. Estimated completion is 2023-06-28.
Who is sponsoring clinical trial NCT07357441?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07133308 · 355 participants · Phase 3
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
- NCT07193511 · 355 participants · Phase 1
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
- NCT06077838 · 356 participants · NA
RELAXaHEAD for Headache Patients (Phase III)
- NCT06293469 · 356 participants · NA
Accelerated Flap Coverage in Severe Lower Extremity Trauma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI